ライフサイエンスコーパス: stavudine

1 retroviral drugs (zalcitabine, didanosine or stavudine).

2 more convenient (specifically didanosine and stavudine).

3 minotransferase levels among patients taking stavudine.

4 d to 5-fold) to didanosine, zalcitabine, and stavudine.

5 sted of zidovudine plus either didanosine or stavudine.

6 sed resistance to AZT, ddI, zalcitibine, and stavudine.

7 received 0.1, 0.5, 1.0, or 2.0 mg/kg/day of stavudine.

8 stance, the primary candidates for replacing stavudine.

9 , 2',3'-dideoxycytidine, dideoxyinosine, and stavudine.

10 a conformational mimic of the anti-HIV agent stavudine (1, D4T) is described.

11 /day), 3TC (Lamivudine 50 mg/kg/day) or D4T (Stavudine 10 mg/kg/day) for 5 days, and cortices, hippoc

12 aboratory) occurred in 104 (67%) children on stavudine, 103 (65%) on zidovudine, and 105 (64%), on ab

13 occurred more frequently in those receiving stavudine (12% in the stavudine group compared with 4% i

14 K65R was frequently selected by stavudine (15.0%) or tenofovir (27.7%).

15 , 2011, 480 children were randomised: 156 to stavudine, 159 to zidovudine, and 165 to abacavir.

16 The antiviral effect of stavudine (2', 3'-didehydro-3'-deoxythymidine) against h

17 or ritonavir, 350 mg/m2 2 times per day, and stavudine, 4 mg/kg 2 times per day (n = 97).

18 F and 253 (84%) of 301 in patients receiving stavudine (95% confidence interval, -10.4% to 1.5%), exc

19 Drugs such as stavudine and didanosine are associated with serious met

20 exhibited low-level cross-resistance to both stavudine and lamivudine in drug susceptibility assays.

21 100 mg twice daily, each in combination with stavudine and lamivudine twice daily, for 48 weeks.

22 ived lopinavir/ritonavir or nelfinavir, plus stavudine and lamivudine, for up to 96 weeks.

23 ir with nelfinavir, each coadministered with stavudine and lamivudine, in 653 antiretroviral therapy-

24 ir versus nelfinavir, each administered with stavudine and lamivudine, in 653 antiretroviral-naive, h

25 reverse-transcriptase inhibitors, especially stavudine and lamivudine, was associated with possible m

26 ween specific drugs and HIV lipohypertrophy, stavudine and zidovudine have been implicated in the dev

27 two daily regimens: 600 mg of zidovudine (or stavudine) and 300 mg of lamivudine, or that regimen wit

28 49.3%) to thymidine analogues (zidovudine or stavudine), and 3683 (47.4%) to protease inhibitors.

29 avir every 8 h with 200 mg nevirapine, 40 mg stavudine, and 150 mg lamivudine, each given twice daily

30 ation [three HAART drugs (3-plex; indinavir, stavudine, and ddI)] at their clinical plasma concentrat

31 nti-HIV nucleoside drugs such as zidovudine, stavudine, and didanosine.

32 a first regimen failure, 0.55); didanosine, stavudine, and efavirenz (hazard ratio, 0.63); or zidovu

33 io for regimen failure, 1.24) or didanosine, stavudine, and efavirenz (hazard ratio, 1.01).

34 ilpivirine, in 27% for tenofovir, in 18% for stavudine, and in 10% for zidovudine.

35 Cross-resistance between zidovudine, stavudine, and lamivudine was studied, using purified re

36 tients were on therapy (lopinavir/ritonavir, stavudine, and lamivudine) with plasma HIV RNA <50 copie

37 e three-drug regimens containing didanosine, stavudine, and nelfinavir (hazard ratio for a first regi

38 ree-drug regimens beginning with didanosine, stavudine, and nelfinavir (hazard ratio for regimen fail

39 for cross-resistance between zidovudine and stavudine, and they suggest a possible effect of zidovud

40 ur previous observations of NRTIs, abacavir, stavudine, and zalcitabine increased HIV-1 mutation freq

41 enofovir, abacavir, lamivudine, zalcitabine, stavudine, and zidovudine.

42 t not efavirenz combined with didanosine and stavudine) appeared to delay the failure of the second r

43 0.61 log(10)copies/mL (4.1 copies/mL) in the stavudine arm (P=.24).

44 stavudine placebo twice daily) (n = 286) or stavudine at standard doses twice daily (plus emtricitab

45 l Treatment Guidelines recommend phasing-out stavudine because of its risk of long-term toxicity.

46 in resistance to zidovudine and >250-fold to stavudine) but not to other nucleoside reverse transcrip

47 Monotherapy with peroral stavudine capsules or peroral zidovudine capsules.

48 increase at 3 years compared to patients on stavudine-containing regimens (2.1 vs 11.7 mg/dL, P < .0

49 ddC) > didanosine (ddI metabolized to ddA) > stavudine (d4T) >> lamivudine (3TC) > tenofovir (PMPA) >

50 Stavudine (d4T) and zidovudine (AZT) are thymidine analo

51 drug substitutions and regimen switches from stavudine (d4T) and zidovudine (AZT) regimens have been

52 e was found to regain sensitivity to AZT and stavudine (D4T) as a consequence of a pharmacologically

53 e safety, tolerance, and pharmacokinetics of stavudine (d4T) in human immunodeficiency virus (HIV)-in

54 ing zidovudine were randomized either to add stavudine (d4T) or didanosine (ddI) to their current reg

55 alcitabine (ddC), didanosine (ddI), 3TC, and stavudine (d4T) were determined, using an enzymatic assa

56 gant multistep continuous flow synthesis for stavudine (d4T), a potent nucleoside chemotherapeutic ag

57 ent effects of the first-line ART containing stavudine (d4T), azidothymidine (AZT) and TDF on death a

58 The NRTIs zidovudine (AZT), stavudine (d4T), didanosine (ddI), and lamivudine (3TC),

59 ZDV)/lamivudine (3TC), ZDV/didanosine (ddI), stavudine (d4T)/3TC, d4T/ddI, and ddI/3TC.

60 rminating 2'-3'-didehydro 3'-deoxythymidine [stavudine (D4T)] and 2'-3'-dideoxyinosine [didanosine (d

61 avir, lopinavir, zidovudine (AZT), abacavir, stavudine, didanosine (ddI), and lamivudine] individuall

62 Severe immunodeficiency, stavudine, didanosine, and indinavir were associated wit

63 ociated with low CD4+ nadir and prior use of stavudine, didanosine, and indinavir.

64 dine or emtricitabine, abacavir, zidovudine, stavudine, didanosine, and tenofovir and a specific GSS

65 e susceptibilities of PERV RT to lamivudine, stavudine, didanosine, zalcitabine, and zidovudine were

66 idence interval, 1.91-6.20]) or who received stavudine-didanosine combination therapy (odds ratio, 2.

67 lamivudine-nevirapine, stavudine-zidovudine, stavudine-didanosine, stavudine-saquinavir, stavudine-ne

68 of PYFU), stavudine/lamivudine (17.6%), and stavudine/didanosine (5.4%).

69 viral therapy duration, smoking, statin use, stavudine/didanosine/zidovudine exposure, time-updated b

70 e was associated with cumulative exposure to stavudine, elvitegravir, and raltegravir.

71 roviral therapy (ART) (P = .02), duration of stavudine exposure (P < .01), low-density lipoprotein ch

72 profiles associated with past zidovudine or stavudine exposure or any interactions between ART drug

73 prior to combination antiretroviral therapy, stavudine exposure was independently associated with hyp

74 -1 resistance mutations following first-line stavudine failure from 35 publications comprising 1,825

75 After stavudine failure in African populations, zidovudine rat

76 sistance patterns associated with first-line stavudine failure.

77 were previously untreated (ART naive) or on stavudine for more than 2 years with viral load less tha

78 rological response < or =50 copies/mL vs the stavudine group (85% vs 76%, P =.005).

79 in the tenofovir DF group compared with the stavudine group (9 [3%] of 299 vs 58 [19%] of 301, P<.00

80 % for the emtricitabine group vs 54% for the stavudine group (P<.001).

81 4% in the emtricitabine group and 12% in the stavudine group (P<.001).

82 tly in those receiving stavudine (12% in the stavudine group compared with 4% in the zidovudine group

83 Patients in the stavudine group had a greater probability of an adverse

84 he risk for death alone was 26% lower in the stavudine group than in the zidovudine group, but the co

85 cell counts were 30 cells/mm3 higher in the stavudine group than in the zidovudine group; this diffe

86 ion error, 156 children were analysed in the stavudine group, 158 in the zidovudine group, and 164 in

87 in 8 and 2 patients in the tenofovir DF and stavudine groups, respectively (P =.06).

88 vir, compared with 29% of patients receiving stavudine, had undetectable residual viremia (P=.07).

89 These data demonstrate that stavudine has a substantial and durable antiviral effect

90 s compared with starting with didanosine and stavudine (hazard ratio, 0.68), and significantly delaye

91 05 (64%), on abacavir (p=0.63; zidovudine vs stavudine: hazard ratio [HR] 0.99 [95% CI 0.75-1.29]; ab

92 io [HR] 0.99 [95% CI 0.75-1.29]; abacavir vs stavudine: HR 0.88 [0.67-1.15]).

93 ir and abacavir have replaced zidovudine and stavudine in antiretroviral regimens, thymidine analog r

94 vudine or a regimen including didanosine and stavudine in combination with either nelfinavir or efavi

95 ganization guidelines on the substitution of stavudine in first-line ART in resource-limited settings

96 sition, involving both abdominal obesity and stavudine-induced peripheral lipoatrophy, might contribu

97 Stavudine is a promising antiretroviral agent, but its c

98 Stavudine is an important agent to consider for trials o

99 arms that included different combinations of stavudine, lamivudine (3TC), nevirapine (Nvp), nelfinavi

100 enz was highly effective and comparable with stavudine, lamivudine, and efavirenz in antiretroviral-n

101 All patients also received stavudine, lamivudine, and indinavir.

102 IV-1) group O-infected patients treated with stavudine, lamivudine, and indinavir.

103 For patients on the first-line regimen of stavudine, lamivudine, and nevirapine the benefits of vi

104 th the WHO-recommended first-line regimen of stavudine, lamivudine, and nevirapine to second-line ant

105 hat significantly more children who received stavudine, lamivudine, nevirapine, and nelfinavir had pl

106 the initiation of therapy and treatment with stavudine, lamivudine, nevirapine, and nelfinavir were a

107 binations: lamivudine-zidovudine, lamivudine-stavudine, lamivudine-saquinavir, lamivudine-nevirapine,

108 erase domain were associated with failure of stavudine-lamivudine-nevirapine (d4T/3TC/NVP; P < .01),

109 ed were zidovudine/lamivudine (66% of PYFU), stavudine/lamivudine (17.6%), and stavudine/didanosine (

110 er 12 months in HIV-positive adults starting stavudine/lamivudine/nevirapine in Malawi, using Sanger,

111 to receive either tenofovir DF (n = 299) or stavudine (n = 303), with placebo, in combination with l

112 ther tenofovir disoproxil fumarate (n=55) or stavudine (n=45), by use of an HIV RNA assay with a limi

113 for tenofovir DF [n = 170] vs +134 mg/dL for stavudine [n = 162], P<.001), total cholesterol (+30 mg/

114 the four-drug regimen containing didanosine, stavudine, nelfinavir, and efavirenz and the groups that

115 stavudine-didanosine, stavudine-saquinavir, stavudine-nevirapine, lamivudine-zidovudine-saquinavir,

116 ith TAMs to lamivudine and abacavir, but not stavudine or didanosine.

117 ir in combination with either didanosine and stavudine or zidovudine and lamivudine with therapy invo

118 ART-naive individuals to receive didanosine-stavudine or zidovudine-lamivudine, combined with efavir

119 h dolutegravir+lamivudine+zidovudine/(one on stavudine) (OR=19.4, 95%CI 5.1-74.3) or dolutegravir+lam

120 uggest an additional reason for accelerating stavudine phase out.

121 her 200 mg of emtricitabine once daily (plus stavudine placebo twice daily) (n = 286) or stavudine at

122 Efavirenz (600 mg/d) and stavudine plus lamivudine were administered in addition

123 o women with HIV-1 infection who were taking stavudine presented with lactic acidosis and elevated le

124 Patients receiving stavudine reached clinical end points at a rate of 26 pe

125 rial dysfunction among children who received stavudine regardless of exposure to other medications (o

126 There are two mutational pathways of stavudine resistance with different implications for zid

127 stavudine-zidovudine, stavudine-didanosine, stavudine-saquinavir, stavudine-nevirapine, lamivudine-z

128 zidovudine-saquinavir, lamivudine-zidovudine-stavudine, stavudine-zidovudine-nevirapine, lamivudine-z

129 oside reverse transcriptase inhibitor (NRTI) stavudine (STV) in mouse cancer models, MMTV-HER2/Neu an

130 ant to the nucleoside analogs lamivudine and stavudine, suggesting that mutations conferring resistan

131 susceptibility to group 1 drugs (zidovudine, stavudine, tenofovir, and adefovir) increased when M184V

132 Here, handling of HIV antivirals (stavudine, tenofovir, lamivudine, acyclovir, and zidovud

133 tase inhibitor (NRTI) backbones (zidovudine, stavudine, tenofovir, or abacavir, plus lamivudine or em

134 udine treatment; these patients could resume stavudine therapy at a lower dose.

135 The benefit of stavudine therapy was seen in all CD4+ cell strata (< or

136 in many patients (63%) after interruption of stavudine treatment; these patients could resume stavudi

137 ed inhibition by zidovudine triphosphate and stavudine triphosphate and, to a lesser extent, lamivudi

138 Stavudine use was associated with lower EF and higher TF

139 Resistance to lamivudine and stavudine was also significantly higher in nelfinavir-tr

140 Stavudine was well tolerated and delayed progression of

141 Exposure to lamivudine and to lamivudine-stavudine were also associated with an increased risk of

142 , and tolerability compared with twice-daily stavudine when used with once-daily didanosine and efavi

143 ial resistance to AZT, ddI, zalcitibine, and stavudine, whereas a combination of four mutations confe

144 and three-drug combinations of lamivudine or stavudine with other antiretroviral drugs were evaluated

145 (80%) and 95 (81%) ART-naive children in the stavudine, zidovudine, and abacavir groups, respectively

146 We aimed to compare stavudine, zidovudine, or abacavir as dual or triple fix

147 The NRTIs were lamivudine + stavudine, zidovudine, or tenofovir.

148 ee-drug combinations, but the combination of stavudine-zidovudine was antagonistic.

149 amivudine-saquinavir, lamivudine-nevirapine, stavudine-zidovudine, stavudine-didanosine, stavudine-sa

150 saquinavir, lamivudine-zidovudine-stavudine, stavudine-zidovudine-nevirapine, lamivudine-zidovudine-n

151 apine, lamivudine-zidovudine-nevirapine, and stavudine-zidovudine-saquinavir.

152 The main ART regimens included stavudine/zidovudine plus lamivudine plus nevirapine/efa